The Explorer Study, published on the Lancet in March 2018, was a high level double blind RCT that showed that the use of sucrose octusalfate can reduce healing time of neuro-ischemic DFUs by 60 days. Previous studies also portrayed reduction in healing time for other chronic wounds such as VLUs and PIs with TLC-NOSF.
During this presentation we will give a very brief overview of the study but moreover show how the international community has reacted to these results. Recently the IWGDG has included TLC-NOSF in their guidelines and NICE (UK) has recommended the use of this modality for all chronic wound patients in the UK. This has also been taken on board by D-Foot International in their DFU referral pathway and over 100 protocols in Europe include the same in their recommendations.
The presentation will also include advice on how to implement a 3 tier program for better referral and management of patients suffering from DFUs.
Emilio Galea started his career in healthcare where he held different positions, from direct patient care, clinical instructor and examiner, managerial positions and Assistant Director of Nursing. His role also included the function of wound management advisor. He was awarded Speaker of the Year Award by the Health Authority of Abu Dhabi. He contributes regularly with articles in wound care journals. Emilio is currently the International Medical Director for URGO Medical. He holds an MSc Skin Integrity (UK). His personal and professional objective is to facilitate, through education, evidence based wound management practice.